155 related articles for article (PubMed ID: 17266627)
1. 3D-QSAR CoMFA study on oxindole derivatives as cyclin dependent kinase 1 (CDK1) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Med Chem; 2007 Jan; 3(1):75-84. PubMed ID: 17266627
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors.
Singh SK; Dessalew N; Bharatam PV
Eur J Med Chem; 2006 Nov; 41(11):1310-9. PubMed ID: 16890327
[TBL] [Abstract][Full Text] [Related]
3. 3D-QSAR CoMFA and CoMSIA study on benzodipyrazoles as cyclin dependent kinase 2 inhibitors.
Dessalew N; Singh SK
Med Chem; 2008 Jul; 4(4):313-21. PubMed ID: 18673142
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, biological evaluation and molecular modeling of a novel series of 7-azaindole based tri-heterocyclic compounds as potent CDK2/Cyclin E inhibitors.
Baltus CB; Jorda R; Marot C; Berka K; Bazgier V; Kryštof V; Prié G; Viaud-Massuard MC
Eur J Med Chem; 2016 Jan; 108():701-719. PubMed ID: 26741853
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR CoMFA on cyclin-dependent kinase inhibitors.
Ducrot P; Legraverend M; Grierson DS
J Med Chem; 2000 Nov; 43(22):4098-108. PubMed ID: 11063606
[TBL] [Abstract][Full Text] [Related]
6. Imidazo[2,1 -b]thiazolylmethylene- and indolylmethylene-2-indolinones: a new class of cyclin-dependent kinase inhibitors. Design, synthesis, and CDK1/cyclin B inhibition.
Andreani A; Cavalli A; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Recanatini M; Garnier M; Meijer L
Anticancer Drug Des; 2000 Dec; 15(6):447-52. PubMed ID: 11716438
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR and molecular docking study on bisarylmaleimide series as glycogen synthase kinase 3, cyclin dependent kinase 2 and cyclin dependent kinase 4 inhibitors: an insight into the criteria for selectivity.
Dessalew N; Bharatam PV
Eur J Med Chem; 2007 Jul; 42(7):1014-27. PubMed ID: 17335939
[TBL] [Abstract][Full Text] [Related]
8. Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.
Mou J; Chen D; Deng Y
Med Chem; 2020; 16(3):307-325. PubMed ID: 31241436
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of potent oxindole CDK2 inhibitors.
Dermatakis A; Luk KC; DePinto W
Bioorg Med Chem; 2003 Apr; 11(8):1873-81. PubMed ID: 12659774
[TBL] [Abstract][Full Text] [Related]
10. Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis.
Bramson HN; Corona J; Davis ST; Dickerson SH; Edelstein M; Frye SV; Gampe RT; Harris PA; Hassell A; Holmes WD; Hunter RN; Lackey KE; Lovejoy B; Luzzio MJ; Montana V; Rocque WJ; Rusnak D; Shewchuk L; Veal JM; Walker DH; Kuyper LF
J Med Chem; 2001 Dec; 44(25):4339-58. PubMed ID: 11728181
[TBL] [Abstract][Full Text] [Related]
11. Evaluation and comparison of 3D-QSAR CoMSIA models for CDK1, CDK5, and GSK-3 inhibition by paullones.
Kunick C; Lauenroth K; Wieking K; Xie X; Schultz C; Gussio R; Zaharevitz D; Leost M; Meijer L; Weber A; Jørgensen FS; Lemcke T
J Med Chem; 2004 Jan; 47(1):22-36. PubMed ID: 14695817
[TBL] [Abstract][Full Text] [Related]
12. 4-Alkoxy-2,6-diaminopyrimidine derivatives: inhibitors of cyclin dependent kinases 1 and 2.
Mesguiche V; Parsons RJ; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Gibson AE; Golding BT; Griffin RJ; Jewsbury P; Johnson LN; Newell DR; Noble ME; Wang LZ; Hardcastle IR
Bioorg Med Chem Lett; 2003 Jan; 13(2):217-22. PubMed ID: 12482427
[TBL] [Abstract][Full Text] [Related]
13. Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition.
Wood DJ; Korolchuk S; Tatum NJ; Wang LZ; Endicott JA; Noble MEM; Martin MP
Cell Chem Biol; 2019 Jan; 26(1):121-130.e5. PubMed ID: 30472117
[TBL] [Abstract][Full Text] [Related]
14. Probing the ATP ribose-binding domain of cyclin-dependent kinases 1 and 2 with O(6)-substituted guanine derivatives.
Gibson AE; Arris CE; Bentley J; Boyle FT; Curtin NJ; Davies TG; Endicott JA; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Mesguiche V; Newell DR; Noble ME; Tucker JA; Whitfield HJ
J Med Chem; 2002 Aug; 45(16):3381-93. PubMed ID: 12139449
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles.
Arris CE; Boyle FT; Calvert AH; Curtin NJ; Endicott JA; Garman EF; Gibson AE; Golding BT; Grant S; Griffin RJ; Jewsbury P; Johnson LN; Lawrie AM; Newell DR; Noble ME; Sausville EA; Schultz R; Yu W
J Med Chem; 2000 Jul; 43(15):2797-804. PubMed ID: 10956187
[TBL] [Abstract][Full Text] [Related]
16. Docking-based development of purine-like inhibitors of cyclin-dependent kinase-2.
Otyepka M; Krystof V; Havlícek L; Siglerová V; Strnad M; Koca J
J Med Chem; 2000 Jun; 43(13):2506-13. PubMed ID: 10891109
[TBL] [Abstract][Full Text] [Related]
17. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
18. Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2.
Sayle KL; Bentley J; Boyle FT; Calvert AH; Cheng Y; Curtin NJ; Endicott JA; Golding BT; Hardcastle IR; Jewsbury P; Mesguiche V; Newell DR; Noble ME; Parsons RJ; Pratt DJ; Wang LZ; Griffin RJ
Bioorg Med Chem Lett; 2003 Sep; 13(18):3079-82. PubMed ID: 12941338
[TBL] [Abstract][Full Text] [Related]
19. Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2.
Lesuisse D; Dutruc-Rosset G; Tiraboschi G; Dreyer MK; Maignan S; Chevalier A; Halley F; Bertrand P; Burgevin MC; Quarteronet D; Rooney T
Bioorg Med Chem Lett; 2010 Mar; 20(6):1985-9. PubMed ID: 20167481
[TBL] [Abstract][Full Text] [Related]
20. Paullones, a series of cyclin-dependent kinase inhibitors: synthesis, evaluation of CDK1/cyclin B inhibition, and in vitro antitumor activity.
Schultz C; Link A; Leost M; Zaharevitz DW; Gussio R; Sausville EA; Meijer L; Kunick C
J Med Chem; 1999 Jul; 42(15):2909-19. PubMed ID: 10425100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
